FolFox4与Xelox一线治疗晚期大肠癌分析

Analysis of the FolFox4 Proposal and Xelox Proposal for Advanced Colorectal Cancer Treatment on Frontline

目的探讨FolFox4与XElox方案一线治疗晚期大肠癌的临床疗效及不良反应。方法将晚期大肠癌患者64例随机分为两组:FolFox4组采用L-OHP 85 mg/m2,CF 200 mg/m2,5-FU 1 000 mg/m2,2周重复1次,28 d为一周期;XElox组采用L-OHP 130 mg/m2、每2周1次,Xeloda 1 800 mg/(m.2d),21 d为一周期。两组都化疗164周期,记录疗效与治疗期间毒副反应。结果 FolFox4组总有效率56.3%(18/32),中位缓解期7.5月,中位生存期11月;Xelox组总有效率46.9%(15/32),中位缓解期、中位生存期分别为7.0月、9.5月。两组在客观疗效以及中位缓解期、中位生存期方面均无显著性差异。结论 FolFox4与XElox方案一线疗效晚期大肠癌客观疗效中位缓解期及中位生存期比较无显著性差异,两组毒副反应均较轻,作为一线治疗晚期大肠癌两方案均可作为首选方案。

Objective Discussing clinical effect and adverse effects of FolFox4 proposal and Xelox proposal for advanced colorectal cancer treatment on frontline. Methods In the study, 64 patients with advanced colorectal cancer are randomly assigned to two teams. FolFox4 team adopts L-OHP 85 mg/m2, CF 200 mg/m2, 5-FU 1 000 mg/m2, repeat the same action every 2 weeks and 28 days as a cycle. Xelox team adopts L-OHP 130 mg/m2, Xeloda 1 800 mg/（mE·d） d1-14, and 21 days as a cycle. It takes 164 cycles for two teams together for chemotherapy. Clinical response and toxic adverse effects shall be recorded. Results The total effect of FolFox4 team is 56.3%（18/32）, the median remission time is 7.5 month, the mediate survival time is l lmonth; meanwhile, The total effect of Xelox team is 46.9%（15/32）, the median remission time is 7.0 month, the mediate survival time is 9.5 month. Therefore, by comparing two teams results, it is concluded that there are not any significant differences for two teams on median remission time and mediate survival time. Goneluaiona In FolFox4 proposal and Xelox proposal for advanced colorectal cancer treatment on frontlinc, there are not any significant differences for the objective effect of colorectal cancer on median remission time and mediate survival time, and toxic adverse effects for two team is not hard; therefore, the two proposal shall be taken as the first option as doing the advanced coloreetal cancer treatment on frontline.